```html

Quasi‑Familial Hypercholesterolemia (QFH)

Overview

Quasi‑familial hypercholesterolemia (QFH) is a hereditary lipid disorder that closely resembles classic familial hypercholesterolemia (FH) but typically presents with a milder biochemical profile and a later onset of cardiovascular disease. The condition is characterized by elevated low‑density lipoprotein cholesterol (LDL‑C) levels that persist from childhood into adulthood, often without the tendon xanthomas or corneal arcus seen in classic FH. QFH is inherited in an autosomal‑dominant pattern, most commonly involving heterozygous mutations in the LDLR, APOB, or PCSK9 genes, but with reduced penetrance compared with FH.

Who it affects: Both men and women are equally susceptible. Because the phenotype is variable, many individuals are only identified after a family member is diagnosed with FH or after a premature cardiovascular event.

Prevalence: Exact figures are still being refined, but recent population‑based studies estimate that QFH may affect roughly 1 in 200–300 people worldwide, compared with 1 in 200‑250 for heterozygous FH. This translates to tens of millions of potential carriers globally.<sup>1</sup>

Symptoms

QFH often remains silent for years, but some patients develop the following signs and symptoms:

• Elevated LDL‑C levels: Typically 190‑280 mg/dL (4.9‑7.2 mmol/L) without treatment.
• Family history of premature coronary artery disease (CAD): Heart attacks or angina before age 55 in men and 65 in women.
• Tendon xanthomas: Small, firm nodules over the Achilles tendon or hands; less common than in FH.
• Corneal arcus: A gray‑white ring around the cornea, usually appearing after age 40.
• Chest pain or angina: May be the first clue if plaque has already formed.
• Peripheral artery disease symptoms: Leg cramps, numbness, or non‑healing ulcers.
• Stroke or transient ischemic attack (TIA): Occasionally the presenting event.

Because many of these signs are non‑specific, laboratory testing is essential for accurate diagnosis.

Causes and Risk Factors

Genetic Basis

• LDLR mutations: Decrease receptor number or function, leading to slower clearance of LDL particles.
• APOB (p.R3527Q) mutations: Impair LDL binding to its receptor.
• PCSK9 gain‑of‑function variants: Increase degradation of LDL receptors.
• Polygenic background: In many QFH patients, a combination of several small‑effect genes raises LDL‑C modestly.

Non‑Genetic Risk Modifiers

• Unhealthy diet high in saturated and trans fats.
• Physical inactivity.
• Obesity (BMI ≥30 kg/m²).
• Smoking or exposure to second‑hand smoke.
• Metabolic conditions such as diabetes or hypothyroidism.
• Certain medications (e.g., glucocorticoids, some antiretrovirals) that raise LDL‑C.

Diagnosis

Diagnosis rests on a combination of clinical assessment, family history, lipid profiling, and—when appropriate—genetic testing.

Step‑by‑step diagnostic pathway

1. Clinical interview and pedigree analysis: Identify early‑onset ASCVD in relatives.
2. Fasting lipid panel:
   • LDL‑C ≥190 mg/dL (4.9 mmol/L) in adults or ≥160 mg/dL (4.1 mmol/L) in children without secondary causes.
   • Total cholesterol often >300 mg/dL (7.8 mmol/L).
3. Screen for secondary causes: Thyroid function tests, liver panel, renal function, fasting glucose/HbA1c.
4. Diagnostic scoring systems: The Dutch Lipid Clinic Network (DLCN) score or Simon‑Broome criteria can be adapted; a score of 3‑5 suggests “possible” QFH.
5. Genetic testing (optional but increasingly recommended): Targeted panel for LDLR, APOB, PCSK9. Identification of a pathogenic variant confirms the diagnosis and enables cascade testing of relatives.

When to refer

• LDL‑C >190 mg/dL in a child or adolescent.
• Any adult with LDL‑C >190 mg/dL plus a family history of premature ASCVD.
• Patients with unexplained atherosclerotic disease before age 55 (men) or 65 (women).

Treatment Options

Treatment aims to lower LDL‑C to a level that minimizes cardiovascular risk while considering patient‑specific factors.

1. Lifestyle Modification (first‑line)

• Diet: Emphasize a Mediterranean‑style diet—plenty of fruits, vegetables, whole grains, legumes, nuts, fish, and olive oil. Limit saturated fat to <10 % of total calories and eliminate trans fats.
• Physical activity: At least 150 minutes/week of moderate‑intensity aerobic exercise (e.g., brisk walking) plus two days of resistance training.
• Weight management: Aim for a BMI 18.5‑24.9 kg/m².
• Smoking cessation: Use nicotine replacement, counseling, or prescription meds (e.g., varenicline).

2. Pharmacologic Therapy

Drug Class	Typical LDL‑C Reduction	Key Points
Statins (e.g., atorvastatin, rosuvastatin)	30‑55 %	First‑line; monitor liver enzymes and CK.
Ezetimibe	15‑20 %	Add-on if LDL‑C target not met with maximally tolerated statin.
PCSK9 inhibitors (evolocumab, alirocumab)	50‑65 %	Injectable; reserved for patients with LDL‑C ≥100 mg/dL despite statin + ezetimibe or statin intolerance.
Bile‑acid sequestrants (e.g., cholestyramine)	10‑20 %	Useful in statin‑intolerant patients; may cause GI upset.
Inclisiran (siRNA therapy)	≈50 %	Administered twice yearly; emerging option.

Guidelines (ACC/AHA 2018, ESC/EAS 2019) suggest an LDL‑C goal of <70 mg/dL for patients with QFH and additional ASCVD risk factors, and <55 mg/dL for those with established disease.

3. Procedural Interventions

• Lipid‑apheresis: Reserved for severe refractory cases (LDL‑C >300 mg/dL) or when rapid LDL reduction is needed before cardiac surgery.
• Coronary revascularization (PCI or CABG): Performed when obstructive coronary disease is documented.

4. Monitoring

• Fasting lipid panel 4–12 weeks after therapy initiation, then every 6–12 months.
• Liver function tests (ALT, AST) within 3 months of starting statins, then annually.
• CK if muscle symptoms develop.

Living with Quasi‑Familial Hypercholesterolemia

Daily Management Tips

• Medication adherence: Use pill organizers or smartphone reminders. Missing doses can quickly raise LDL‑C.
• Food labeling: Check Nutrition Facts for saturated fat (<10 g per serving) and avoid “partially hydrogenated” oils.
• Regular check‑ups: Keep appointments with a lipid specialist or cardiologist; bring a list of all medications and supplements.
• Family communication: Encourage first‑degree relatives to get screened; cascade testing can catch affected members early.
• Stress management: Chronic stress may affect lipid metabolism; practice mindfulness, yoga, or counseling as needed.
• Physical activity logs: Record exercise duration and intensity to stay accountable.

Psychosocial Considerations

Living with a genetic condition can cause anxiety. Join support groups (e.g., FH Foundation), seek counseling, and discuss reproductive options (e.g., prenatal testing or pre‑implantation genetic diagnosis) with a genetic counselor if planning a family.

Prevention

While you cannot change the inherited component, you can dramatically lower overall cardiovascular risk by:

• Adopting the lifestyle measures outlined above.
• Maintaining optimal blood pressure (<130/80 mmHg) and glycemic control.
• Regular aspirin therapy (81 mg daily) may be appropriate for those with additional risk, after consulting a physician.
• Vaccinations (influenza, COVID‑19, pneumococcal) to reduce infection‑related inflammation.

Complications

If untreated or inadequately treated, QFH can lead to:

• Atherosclerotic cardiovascular disease (ASCVD): Myocardial infarction, stable/unstable angina, heart failure.
• Ischemic stroke or TIA: Due to carotid or cerebral artery atherosclerosis.
• Peripheral artery disease (PAD): Claudication, ulceration, risk of limb loss.
• Aortic valve calcification: May cause stenosis requiring surgical replacement.
• Pancreatitis: Rarely from severe hypertriglyceridemia if secondary lipid abnormalities coexist.
• Psychological impact: Depression or anxiety related to chronic disease management.

When to Seek Emergency Care

---

References

1. Nordestgaard BG, et al. “Familial hypercholesterolaemia and the role of cascade screening.” World J Cardiol. 2020;12(8):291‑301. DOI:10.4330/wjc.v12.i8.291.
2. American College of Cardiology/American Heart Association. “2018 Guideline on the Management of Blood Cholesterol.” Circulation. 2019;139:e1082‑e1143.
3. European Society of Cardiology/European Atherosclerosis Society. “2021 ESC/EAS Guidelines for the Management of Dyslipidaemias.” European Heart Journal. 2021;42:3227‑3529.
4. U.S. National Library of Medicine. “PCSK9 Inhibitors.” NIH MedlinePlus. Updated 2023.
5. World Health Organization. “Cardiovascular disease (CVD) risk charts.” 2022.
6. Mayo Clinic. “High cholesterol — symptoms and causes.” Accessed April 2024.
7. Cleveland Clinic. “Lifestyle changes to lower cholesterol.” Updated 2023.

```